Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT05604248 |
Other study ID # |
E43035 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
April 1, 2023 |
Est. completion date |
July 8, 2023 |
Study information
Verified date |
October 2022 |
Source |
Cheikh Anta Diop University, Senegal |
Contact |
Nicole Idohou-Dossou,, Pr |
Phone |
775691311 |
Email |
nicole.dossou[@]ucad.edu.sn |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Vitamin A deficiency (VAD) is still a serious public health problem in most developing
countries. Several strategies are used to prevent and address the consequences of this
deficiency and to reduce its prevalence, particularly in Africa. In Senegal, the prevalence
of VAD, although low among women of reproductive age, is quite worrying among children under
5 years old. In 2009, the fortification of refined oil with vitamin A was made mandatory in
addition to the strategies already in place. The study of the impact of these strategies on
the vitamin A status of women and children, showed relatively stable prevalences between 2010
and 2018. However, this study used plasma retinol concentration as an indicator. It is known
that evaluation of vitamin A status is relatively insensitive when based on changes in plasma
retinol concentrations, which are homeostatically controlled and negatively affected by
subclinical infections. Incremental studies in the Dakar region using the modified relative
dose response (MRDR) test in children under 2 years of age have indicated adequate vitamin A
stores and a low prevalence of vitamin A deficiency in these children. The various strategies
to prevent and control vitamin A deficiency have reportedly improved and even increased
vitamin A stores in women and children, particularly in the Dakar region. Indeed, the latter
benefit from substantial intakes of preformed retinol through the fortification program, and
the majority of children under 2 years of age are breastfed.
The aim of this study is to use a more sensitive method than plasma retinol, the retinol
isotope dilution (RID) test, to assess the actual status of subjects following these
different strategies and to better orient the policies implemented in Senegal.
Description:
Specifics objectives are:
To determine transfer of tracer to breast milk To determine the composite coefficient (FaS)
using mathematical modeling To estimate TBS using the generated coefficients and the RID
equation among mothers To estimate TBS from breast milk retinol using the mass balance
equation among mothers To estimate TBS from serum retinol using the mass balance equation
among mothers and their children To assess the agreement between TBS measured by different
methods (the RID equation, the mass balance equation using serum or breast-milk derived
retinol) among mothers To evaluate the relationship between mothers' and children's TBS
according to their status To assess dietary intakes of vitamin A among mother-child pairs
The study is designed following a "Wonder women model". It will be implemented in Dakar city.
A total of fifty-six (56) lactating mother-child pairs will be included in the study. The
women will be divided into 8 groups of 7 women each. This sample size includes an attrition
rate of 15%.
At baseline (day 0), blood samples will be obtained from all the women after an overnight
fast. Women will also be asked to give casual milk samples. Then, each woman will be given an
oral dose of 2.0 μmol 13C2 -retinyl acetate (Gannon et al., 2014; Kaliwile et al., 2021).
Afterward, participants will consume a peanut butter-based snack to provide fat to improve
dose absorption. The women will also have a follow-up sample taken at day 14. As for
baseline, a follow-up milk sample will be collected. Short-term sampling of both blood and
milk will occur between days 0 and 14 and between days 14 and 109. In total, each woman will
have 4 blood and 4 milk samples taken over time.
For infants, the RID test will start at day 14. After the baseline blood, they will receive
1.0 μmol 13C2-retinyl acetate and will have a second blood sample at day 28. Thus, infants
will have 2 blood samples.
The protocol will be explained to the mother and written consent will be obtained from her.
Lactating mother-infant pairs will be dewormed before starting the research protocol.
The blood samples will be protected from light with aluminum foil and centrifuged at 3500 rpm
for 15 minutes to separate serum from clot. All centrifugations will be done in the hour
following the blood sampling and using a centrifuge. The serum will be aliquoted into sterile
cryogenic vials and stored at -80 °C at the laboratory.
Regarding milk samples, 2 aliquots will be prepared in 2 cryovials and stored at +4°C in the
field and at -80°C at the laboratory.
An interviewer-administered questionnaire will allow collection of background information and
dietary data from mother-infant pairs. Dietary intakes of mother-infant pairs will be
assessed using 2 quantitative 24-hour dietary recalls on non-consecutive days (FAO, 2018).
The Minimum Dietary Diversity for Women (MDD-W) will also be determined from the 24-hour
dietary recalls. For children, Infant and Young Child Feeding practices indicators will be
assessed following the latest WHO/UNICEF recommendations (WHO/UNICEF, 2021).
Anthropometric measurements will be performed to evaluate the nutritional status of
mother-infant pairs according to standard procedures.
Sample analysis:
Serum Retinol concentration will be done by HPLC. Natural abundance of 13C in serum and milk
will be measured by Gas Chromatography-Combustion-Isotope Ratio Mass Spectrometry
(GC-C-IRMS). CRP and AGP will be measured by Biosystems A15 automatic analyzer. Retinyl
esters and serum carotenoids will be done by Ultra-Performance Liquid Chromatography (UPLC).
Anemia will be assessed by measuring hemoglobin (Hb) in whole blood using a HemoCue system
(Hb-301) and malaria testing will be performed using SD BIOLINE Malaria Antigen P.f/Pan1
tests.
Further analysis will be done on saliva samples in a subsample of mother-child pair to
measure milk production by the mother-dose deuterium isotope dilution method. Deuterium
enrichment of saliva samples will be measured with a Fourier transform infrared spectrometer
(FTIR Shimadzu IR Affinity, Kyoto, Japan).
Modelling retinol kinetics among mothers :
Serum and breast milk retinol concentrations and isotope enrichment data will be used to
generate super women data sets. Model-based compartmental analysis will be applied to super
women isotope tracer data for serum and breast milk enrichment using established models for
vitamin A metabolism (Green et al., 2020; Gannon et al., 2018) and expanding these models to
incorporate tracer transfer to breast milk.
Determination of Fa and S factors:
Outputs from the model-based compartmental analysis include estimates for vitamin A transfer
rates among physiologically-based compartments and the resulting model outcomes; total traced
mass, half-life, fractional catabolic rate, disposal rate, equilibration time, and serum/body
tracer partitioning (factor S). Using absorption assumptions, the amount of tracer dose
absorbed and stored at the time of sampling (related to factor Fa and other related equation
coefficients) will be determined.
TBS calculation:
Mass balance equation: The isotopic ratio of tracer to tracee (TTR) (unlabeled retinol) in
serum will be used to estimate total body VA stores (TBS) using the following equation with
appropriate assumptions:
TBS (μmol)= a × 1/TTR× (factors for correction of absorption and storage) a is the dose
amount RID equation: TBS (μmol)= Fa × S × (1/〖SAp〗) Fa is the fraction of the oral tracer
dose absorbed and retained in stores S is the ratio of the specific activity of retinol
(labeled retinol/unlabeled retinol) in plasma to that in liver after dose equilibration SAp
is the specific activity of retinol (labeled retinol/unlabeled retinol) in plasma.
For mothers, Fa and S will be calculated using mathematical modelling while SAp will be
analytically determined. Among children, generic values for Fa and S will be used.
Statistical analysis:
Data entry and quality control will be performed using Epi infoTM 7.2.3.1, Epi infoTM 3.5.1
(Centers for Disease Control and Prevention) and Microsoft Excel 2016 (Microsoft
Corporation). Statistical analysis will be performed using STATA/SE 14.0 (STATA Corporation).
Descriptive analysis will be used to tabulate the characteristics of the study population.
Categorical variables will be expressed as percentages, and continuous variables as mean ± SD
for normally distributed variables and median with interquartile range for skewed values.
Two-tailed Student's t- test, Paired t-test or one-way analysis of variance (ANOVA) followed
by Bonferroni's post-hoc comparison tests will be used to compare means while the Wilcoxon
rank-sum test will be used to compare medians. Pearson's chi-squared test, Fisher's exact
test or McNemar's chi-square test will be used to compare percentages. Appropriate agreement
tests will be performed. All the statistical analysis stages will be performed by an
experienced statistician using appropriate methodology to ensure proper and reliable
outcomes.